[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]

Synergy drug discovery platform is based on Antibody-Targeted Endostatin Payload (ATEP) technology. ATEP is a fully biological payload that genetically fuses a highly efficient variant of endostatin, endostatin-P125A, to an antibody in a specific manner for efficient delivery to anti-angiogenic therapeutic.